

1
2
3
4
5
6
7

**Final – Minutes
Toxicology Subcommittee of the
Scientific Advisory Committee**

May 7, 2019

Department of Forensic Science, Central Laboratory, Classroom 1

8
9

Subcommittee Members Present

10 Maureen C. Bottrell
11 Leslie E. Edinboro, Ph.D., Chair
12 Barry S. Levine, Ph.D.
13 Richard P. Meyers
14

15
16

Subcommittee Members Absent

17 Jami J. St. Clair
18

19
20

Committee Members Present

21 Linda C. Jackson
22

23
24

Staff Members Present

25 Amy M. Curtis, Department Counsel
26 Carisa M. Studer, Legal Assistant
27 David A. Barron, Ph.D., Deputy Director
28 Alka B. Lohmann, Director of Technical Services
29 James W. Hutchings, Ph.D., Toxicology Program Manager
30 Katya N. Herndon, Chief Deputy Director
31 Rebecca L. Wagner, Ph.D., Research Section Supervisor

32
33

Call to Order

34 Leslie Edinboro, Ph.D., the Chair of the Scientific Advisory Committee's Toxicology
35 Subcommittee ("Subcommittee"), called the meeting to order at 8:31 a.m.
36

37
38

Adoption of the Agenda

39 Dr. Edinboro asked if there were any additions or changes to the draft agenda for the meeting. Ms.
40 Bottrell made a motion to adopt the agenda; the motion was seconded by Dr. Levine and adopted
41 by unanimous vote of the Subcommittee.
42

43
44

Discussion of Validations

45 The members of the Subcommittee were provided copies of the Virginia Department of Forensic
46 Science's (DFS or the Department) Validation Summary of the Qualitative Analysis of Novel

47 Psychoactive Substances using LCMSMS and the Validation Summary of Fentanyl Analog
48 Qualitative Analysis by Protein Precipitation using LCMSMS in advance of the meeting. Dr.
49 Hutchings and Dr. Wagner gave an overview of the two validation summaries to the Subcommittee
50 members. Dr. Edinboro led a discussion between the Subcommittee members and DFS staff
51 regarding the two validations. Dr. Hutchings and Dr. Wagner answered the Subcommittee
52 members' questions regarding the validations. The Subcommittee members provided comments
53 and made suggestions for DFS to consider for the two validation documents.
54

55 **Discussion of Methods in Development**

56
57 The members of the Subcommittee were provided copies of the following Toxicology methods in
58 development: Confirmation and Quantitation of Fentanyl Derivatives in Biological Samples by
59 Solid Phase Extraction Using LCMSMS; Qualitative Drug Screening Using High Resolution Mass
60 Spectrometry; GHB, GBL, and 1,4-Butanediol Quantitation and Confirmation Method by
61 LCMSMS; and Nonsteroidal Anti-inflammatory Drug Quantitation and Confirmation Method by
62 LCMSMS.
63

64 Dr. Wagner gave an overview of each method in development to the Subcommittee. Dr. Edinboro
65 led a discussion between the Subcommittee members regarding the four methods in development.
66

67 Maureen Bottrell made a motion to have the Department consider the Subcommittee's
68 recommendations made for the validations and methods in development, specifically regarding
69 carryover, retention time criteria, the use of relative retention time for identification purposes, and
70 the ion ratio algorithm (sliding scale). The motion was seconded by Dr. Levine, and passed by
71 unanimous vote.
72

73 Richard Meyers made a motion to close the Subcommittee's review of the Toxicology validations
74 and methods in development; the motion was seconded by Dr. Levine, and passed by unanimous
75 vote.
76

77 **Public Comment**

78
79 None.
80

81 **Future Meeting Date**

82
83 Mr. Meyers made a motion to adjourn the meeting of the Toxicology Subcommittee; the motion
84 was seconded by Dr. Levine and passed by unanimous vote.
85

86 The meeting adjourned at 9:58 a.m.